The recent operational and strategic activities of Astellas Pharma Inc. have indicated significant strides towards their goal of making notable impacts on healthcare. The company has had several of its therapies clear regulatory hurdles. FDA has endorsed Astellas' gastric cancer therapy and the firm's VYLOY for treatment of advanced gastric and GEJ Cancer, with the UK regulator also giving a nod to the gastric cancer therapy. A new innovative digital health product has been introduced to the US market, and a digital solution for heart failure patients is also on the horizon.
A significant partnership deal worth US$2.2bn for gene therapy has been signed with AviadoBio Ltd. Research collaborations have been set up with the likes of UMass Chan Medical School, Osaka University, and others to develop novel therapies. Moreover, Astellas has shown its commitment towards innovation by establishing a new Life Sciences Center in Cambridge, to accelerate the discovery of breakthrough therapies.
However, challenges have occurred. The company withdrew its Europe ACP application for AMD treatment and its gene therapy production facility in the U.S is slated for closure. Furthermore, an indictment by China's prosecutors involves an Astellas employee.
Astellas Pharma Inc. News Analytics from Thu, 01 Apr 2021 00:38:44 GMT to Wed, 06 Nov 2024 21:22:55 GMT -
